Author:
Hussey Elizabeth K.,Donn Karl H.,Powell J. Robert
Abstract
A new extended‐release formulation of albuterol, Volmax, was developed based on the oral osmotic drug delivery system. Proventil Repetabs, another extended‐release formulation of albuterol, is a repeat‐action tablet. The steady‐state pharmacokinetic profile of Volmax 8 mg orally every 12 hours for 3 days was compared with that of Proventil Repetabs 8 mg orally every 12 hours for 3 days in a randomized, two‐way, crossover study in 23 healthy men. Results were determined for both daytime and nighttime dosing intervals. Volmax demonstrated significantly less peak‐trough fluctuation during both dosing intervals than Proventil Repetabs (p < 0.05). Peak plasma concentrations were higher and occurred earlier with Proventil Repetabs. There were no significant differences between the two formulations with respect to reported adverse experiences. Volmax exhibited a more controlled release of albuterol during both daytime and nighttime dosing intervals than Proventil Repetabs.
Reference18 articles.
1. A summary of the pharmacology and toxicology of albuterol (Proventil);Tabachnick HA.;Ann Allergy,1981
2. Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial;Finch JS.;Ann Allergy,1981
3. Bronchodilators in Asthma
4. Bronchodilator drugs;Paterson JW;Am Rev Respir Dis,1979
5. Infantile bronchial asthma